Beta-adrenergic function in heart muscle disease and heart failure.
Using data derived from clinical and experimental observations, we examine the role of the myocardial beta-adrenergic receptor system in pathophysiologic processes involved in heart muscle disease and heart failure. The available data suggest that the sympathetic nervous system exerts important influences on myocardial structure and function. As such the beta-adrenergic pathways represents an obvious locus for therapeutic intervention in evolving cardiomyopathic states.
Bristow
M R
MR
Kantrowitz
N E
NE
Ginsburg
R
R
Fowler
M B
MB
D000262:Adenylyl Cyclases / Q000378:metabolism; D000318:Adrenergic beta-Agonists / Q000009:adverse effects / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000818:Animals; D002118:Calcium / Q000378:metabolism; D009202:Cardiomyopathies / Q000378:metabolism / Q000503:physiopathology*; D002316:Cardiotonic Agents / Q000627:therapeutic use; D002395:Catecholamines / Q000494:pharmacology / Q000502:physiology* / Q000633:toxicity; D000242:Cyclic AMP / Q000502:physiology; D004347:Drug Interactions; D004361:Drug Tolerance; D006168:Guinea Pigs; D006333:Heart Failure / Q000378:metabolism / Q000503:physiopathology*; D006801:Humans; D009200:Myocardial Contraction / Q000187:drug effects; D009203:Myocardial Infarction / Q000378:metabolism / Q000503:physiopathology; D009206:Myocardium / Q000378:metabolism; D011817:Rabbits; D011943:Receptors, Adrenergic, beta / Q000378:metabolism / Q000502:physiology*; D012508:Sarcolemma / Q000378:metabolism
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D002316:Cardiotonic Agents; D002395:Catecholamines; D011943:Receptors, Adrenergic, beta; D000242:Cyclic AMP; D000262:Adenylyl Cyclases; D002118:Calcium